The efficacy of small-molecule kinase inhibitors has recently changed standard clinical practice for several solid cancers. Glioblastoma is a solid cancer that universally recurs and unrelentingly results in death despite maximal surgery and radiotherapy with concomitant and adjuvant temozolomide. Several clinical studies using kinase inhibitors in glioblastoma have been reported. The present study systematically reviews the efficacy, toxicity, and tissue analysis of small-molecule kinase inhibitors in adult patients with glioblastoma as reported in published clinical studies and determines which kinases have been targeted by the inhibitors used in these studies. Publications were retrieved using a MEDLINE search and by screening meeting abstracts. A total of 60 studies qualified for inclusion, of which 25 were original reports. A total of 2385 glioblastoma patients receiving kinase inhibitors could be evaluated. The study designs included 2 phase III studies and 37 phase II studies. Extracted data included radiological response, progression-free survival, overall survival, toxicity, and biomarker analysis. The main findings were that (i) efficacy of small-molecule kinase inhibitors in clinical studies with glioblastoma patients does not yet warrant a change in standard clinical practice and (ii) 6 main kinase targets for inhibitors have been evaluated in these studies: EGFR, mTOR, KDR, FLT1, PKCb, and PDGFR.
S mall-molecule compounds that inhibit the kinase domain of specific kinase targets have recently changed clinical practice for several advanced solid cancers, such as lapatinib, which inhibits HER2 and EGFR in HER2-positive metastatic breast cancer; 1 sunitinib, which inhibits VEGFR and PDGFR in metastatic renal-cell carcinoma; 2 and sorafenib, which inhibits RAF, PDGFR, VEGFR, and KIT in advanced hepatocellular carcinoma 3 and also in advanced renalcell carcinoma. 4 These advances followed the seminal contribution to cancer therapy by gefitinib for chronic myeloid leukemia by inhibiting the ABL/CBR fusion protein 5 and for gastrointestinal stroma tumor by inhibition of the activating KIT mutation. 6 Glioblastoma is one of the most aggressive solid cancers and the most common primary brain tumor. Because this tumor is inherently resistant to conventional therapy, the median patient survival is approximately 14 months. Although standard treatment with surgery, irradiation, and temozolomide postpones progression and extends survival to some extent, these tumors universally recur and unrelentingly result in death. 7 Therefore, improvement of treatment options for patients with glioblastoma is imperative. For this purpose, inhibition of kinase targets that drive glioblastoma growth seems a reasonable treatment strategy to be further explored.
Several clinical studies have reported the efficacy of kinase inhibitors in glioblastoma. The outcome of these clinical studies has not been systematically reviewed, although a number of reviews highlight in their discussions a selection of studies using kinase inhibitors for glioblastoma. 8 -15 The aim of the present study was to review the efficacy of small-molecule kinase inhibitors in adult patients with glioblastoma based on published clinical study results and to determine which kinases are targeted by the inhibitors used in these clinical studies.
Search Strategy and Data Extraction
Results of clinical studies were obtained from 2 sources. A systematic search was performed in PubMed MEDLINE with the MeSH term "glioma" limited by publication type "clinical trial" and "adults", with publication after January 1, 2002 To compare the data obtained from studies without control patient groups, the results from published studies in patients with newly diagnosed and progressive glioblastoma receiving conventional therapy were included as historical controls.
The data extracted from these sources were the total number of patients in the study, the number of evaluated patients in the population used for data extraction, histopathological diagnosis, study design, type of inhibitor and dosage, inhibitor target, percentage of radiologically complete responses and partial responses, median progression-free survival (mPFS), PFS at 6 months (PFS6), median overall survival (mOS), OS at 12 months (OS12), the number of adverse events of grade 3, 4, or 5 according to the National Cancer Institute Common Toxicity Criteria, and the tissue analysis in relation to response. Data on the effect of kinase inhibitors on the functional status of patients were unavailable from the vast majority of evaluable studies. As far as possible, the data were extracted for the glioblastoma subgroup. When exact percentages and survival times were not provided, these were estimated from the time to progression and survival curves.
Publications and abstracts were screened for efficacy data. Audiovisual material at the ASCO website (http:// www.asco.org/ASCOv2/Meetings/Abstracts) was available for some of the meeting presentations and was scanned for additional data not included in the meeting abstract. If no outcome data (ie, radiological response, PFS, or OS) were provided, the publication or abstract was excluded from the analysis.
Meta-analysis of the efficacy data was not performed because of the small sample sizes and the highly selected populations with inhomogeneity of inclusion criteria, histopathological diagnosis, stages of disease, drug schedules, and definitions of outcome and efficacy. Therefore, analysis of data is descriptive and qualitative.
Results
A total of 60 studies qualified for inclusion, of which 25 were published as original reports in peer-reviewed journals and 35 as meeting abstracts. Study designs included 2 phase III studies, 1 randomized phase II study, 28 single-arm phase II studies, 8 single-arm phase I/II studies, 16 phase I studies, 4 retrospective observational series, and 1 pharmacodynamic study. The sum of evaluated patients receiving kinase inhibitors was 2385. The average number of evaluable patients per study was 40, ranging from 6 to 178.
The efficacy, toxicity, and tissue analysis results are listed in Table 1 .
Radiological Response
Radiological response rates (ORs) were evaluable in 51 studies.
The reported objective radiological ORs were approximately double the baseline rates after inhibition of EGFR using erlotinib or gefitinib in 6 of 12 evaluable single-inhibitor studies, in 2 of 7 studies combining inhibition of EGFR and mTOR, and in none of 4 evaluable studies combining EGFR inhibition with conventional therapy. In 1 study combining EGFR inhibition by erlotinib with VEGF inhibition by bevacizumab, an OR of 48% was observed, 16 which was comparable with the results for pan-VEGFR inhibition with cediranib. 17 The ORs after inhibition of mTOR were comparable with the baseline results in 4 single-agent studies. Inhibition of PKCb by enzastaurin increased the OR compared with baseline in 1 of 3 studies. Two of 6 single-agent studies using PDGFR/KIT/ABL inhibition by imatinib and 3 of 5 combination therapy studies with imatinib and hydroxyurea showed an increased OR. The combination of imatinib, hydroxyurea, and KDR inhibition by vatalanib resulted in increased ORs in 2 of 2 studies.
Progression-Free Survival
The PFS was evaluable as mPFS in 36 studies and as PFS6 in 34 studies.
The mPFS approximately doubled in progressive glioblastoma compared with baseline in 1 of 8 evaluable studies with EGFR inhibition by gefitinib or erlotinib 18 and in 1 of 6 evaluable studies with combined EGFR and mTOR inhibition using gefitinib at high dose. 19 Seven evaluable studies combining EGFR inhibition with conventional therapy had PFS comparable with baseline values. The mPFS was comparable with baseline in 3 evaluable studies with single-agent mTOR inhibition. The remarkable OR of VEGFR inhibition by cediranib was substantiated by a slightly increased mPFS of 4 months. 17 The mPFS was increased in 2 of 4 evaluable studies with imatinib as single-agent therapy, although a relevant number of anaplastic gliomas were included in these 2 studies. 20, 21 One of 3 evaluable studies using combined imatinib and hydroxyurea showed a small increase in mPFS of 3.6 months compared with baseline. 22 The PFS6 was comparable with baseline in all 8 evaluable studies with EGFR inhibitors as single-agent therapy, was possibly increased in 2 of 5 evaluable studies with combined EGFR and mTOR inhibition including 1 study with a number of anaplastic gliomas, 23, 24 and was increased in 1 of 4 evaluable studies with EGFR inhibition combined with conventional therapy, which included a relevant number of anaplastic gliomas. 25 When EGFR inhibition was combined with VEGFR ligand binding by bevacuzimab, the PFS6 was 24%. 16 The PFS6 was comparable with baseline using both evaluable single-agent mTOR inhibitors. 26, 27 In both studies with single-agent VEGFR inhibitors, the PFS6 was increased, including a PFS6 of 30% after cediranib in concordance with the increased OR and mPFS. 17, 28 The PFS6 was comparable with baseline in 1 evaluable study with PKCb inhibition. The same 2 studies with single-agent imatinib that had an increased mPFS also had an increase in PFS6. 20, 21 Again, the number of anaplastic gliomas included in the study populations likely contributed to this finding. A slight increase in PFS6 was observed in 2 of 4 evaluable studies with combination therapy using imatinib and hydroxyurea, while 1 of these 2 studies was a retrospective observational series. 22, 29 Furthermore, the study with combined imatinib, hydroxyurea, and KDR inhibition by vatalanib had a PFS6 of 27%, although a number of anaplastic gliomas were included. 30 
Overall Survival
The OS was evaluable as mOS in 23 studies and as OS12 in 12 studies. The mOS increased to 9.9 months in 1 of 5 evaluable studies with single-agent EGFR inhibition. 31 In the 1 evaluable study with combined EGFR and mTOR inhibition, the mOS was also increased. 19 The mOS was remarkably increased to 19.3 months in 1 of 6 evaluable studies with the combination of EGFR inhibition and conventional therapy, erlotinib, and temozolomide in this study with newly diagnosed glioblastomas. 32 Another study with combination therapy using EGFR inhibition by gefitinib and radiosurgery showed an increased mOS; however, anaplastic gliomas were included. 25 The one evaluable study with single-agent mTOR inhibition had an mOS comparable with baseline. The 1 evaluable study with VEGFR inhibition by cediranib, with encouraging OR, mPFS, and PFS6, barely presented an increase in mOS. 17 The mOS was comparable with baseline in 2 evaluable studies with PKCb inhibition by enzastaurin. In 1 of 4 evaluable studies with imatinib as single-agent therapy, the mOS was increased, although a substantial number of anaplastic gliomas were included. 20 The mOS was increased in 2 of 3 evaluable studies with imatinib in combination with hydroxyurea; of these 2 studies, 1 included a number of anaplastic gliomas 33 and the other showed an mOS of 12.2 months in progressive glioblastoma. 22 The OS12 was increased to 36% in 1 of 5 evaluable studies with EGFR inhibition. 26 In 1 of 2 evaluable studies with EGFR inhibition by erlotinib combined with temozolomide, the OS12 was increased to 68%. 32 In 1 evaluable study with PKCb inhibition by enzastaurin, the OS12 was comparable with baseline. 34 The OS12 was increased to 45% in 1 of 2 evaluable studies with imatinib as single-agent therapy, which included a large number of anaplastic gliomas. Combination therapy using imatinib and hydroxyurea increased the OS12 in both evaluable studies. 29, 35 Toxicity Toxicity data were evaluable in 26 studies.
The toxicity increased to 27 events in 55 patients in 1 of 7 evaluable studies with EGFR inhibition by gefitinib compared with baseline. 31 The toxicity of therapy combining EGFR and mTOR inhibition was increased up to 36 events in 32 patients in 2 of 6 evaluable studies. 24, 36 Toxic events associated with therapy combining EGFR inhibition by erlotinib with conventional therapy, such as temozolomide, 32 carboplatin, 37 or temozolomide, and radiotherapy 38 were considerably increased, with 48 events in 65 patients, 82 in 43 patients, and 40 in 27 patients, respectively. In 3 of 4 evaluable studies with mTOR inhibition by rapamycin or temsirolimus, toxicity was increased up to 49 events in 43 patients. 26, 27, 39 The toxicity was increased in 1 of 2 studies with VEGFR inhibition by cediranib 17 and was not increased with PKCb inhibition. Imatinib was associated with increased toxicity (35 events in 55 patients) in 1 of 5 evaluable studies. 40 The combination therapy of imatinib and hydroxyurea showed increased toxicity (up to 8 events in 16 patients) in 2 of 4 evaluable studies. 22, 41 
Tissue Analysis
Patient tissue was analyzed in relation to response in 27 studies. The activation status of a substrate downstream of the kinase target was verified in 4 studies after EGFR inhibition 42 -45 and in 2 studies after mTOR inhibition, 27, 39 of which 3 provided an indication of target inactivation after kinase inhibition. 27, 39, 43 Several molecular markers have been found to predict response, sometimes with conflicting results.
An association between tissue analysis and response to EGFR inhibition was identified in 3 of 10 studies that analyzed tissue. In one of these studies, the presence of the EGFRvIII mutant correlated with poor PFS after erlotinib. 45 In the second study, the presence of the EGFRvIII mutant coinciding with PTEN protein expression was associated with radiological response after erlotinib or gefitinib. 46 In the third study, high EGFR protein expression, EGFR amplification, and low phosphorylated AKT protein expression, as a downstream target of EGFR, each correlated with radiological response, and in addition, high phosphorylated AKT protein expression was associated with poor PFS. 43 A response correlation was found in 2 studies describing tissue analysis after mTOR inhibition. In one study, high protein expression of phosphorylated PRAS40, as a downstream target of AKT, correlated with poor PFS after rapamycin. 39 In the other study, high protein expression of phosphorylated S6K, as a downstream target of mTOR, was associated with radiological response after temsirolimus. 27 After VEGFR inhibition by cediranib, radiological tumor progression was associated with a decrease in the plasma protein level of PIGF and an increase in plasma protein levels of sVEGFR2, bFGF, and SDF1a. 17 A survival benefit was identified in patients with both a methylated MGMT promotor status and positive PTEN protein expression after combination therapy of EGFR inhibition by erlotinib and temozolomide during and after radiotherapy. 32 
Kinase Drug Targets
The targets of small-molecule kinase inhibitors in clinical studies with glioblastoma patients have mainly been 6 kinases: EGFR, mTOR, KDR, FLT1, PKCb, and PDGFR. In addition, 3 evaluated multitargeted agents also inactivate other kinase targets nonspecifically: imatinib also inhibits KIT and ABL, sunitinib also inhibits FLT3 and RET, and lapatinib also inhibits HER2.
Discussion
The main findings of the present study are that (i) the efficacy of small-molecule kinase inhibitors in clinical studies with adult glioblastoma patients does not yet warrant a change in standard clinical practice, and (ii) the main kinase targets of the inhibitors evaluated in these studies are EGFR, mTOR, KDR, FLT1, PKCb, and PDGFR.
The evaluated studies have several limitations that should be considered in interpreting these results. First, many of the studies were not designed to determine the efficacy of therapy and consequently no control group was included for comparison of results in the intervention group. Included in this analysis were outcome results from 4 retrospective observational, 1 pharmacodynamic, 16 phase I, and 8 phase I/II studies. Control group data were available from 1 randomized phase II and 2 phase III studies. Second, sample sizes were small. For instance, the average number of patients in the phase II studies was 39 (range: 12 -65) . Third, the study populations predominantly consisted of patients with progressive glioblastoma or anaplastic glioma, except for 9 studies of patients with newly diagnosed glioblastoma. Fourth, drug activity was usually unknown, as the inactivation of downstream targets was seldom verified in tissue samples. Fifth, the classical study endpoints of radiological response, PFS, and OS were evaluated, each with their limitations. Beneficial effects for individual patients, for instance in terms of improved quality of life or alleviation of symptoms, cannot be excluded by evaluation of these classical endpoints. As an example of the limitations of the classical endpoints, the radiological response criteria rely on enhancement due to blood-brain barrier disruption. Causes other than tumor progression can induce enhancement, such as postoperative gliosis, infection, or radiation necrosis, and enhancement can be reduced by stabilization of the blood-brain barrier rather than by a decrease of the tumor burden. Furthermore, limitations to the PFS as an endpoint are inherent to the radiological definition of progression, its dependence on timing of radiological follow-up, and the fact that radiological progression is not necessarily equal to cessation of clinical benefit. Evaluation of the OS is hampered by bias from subsequent salvage therapies after the trial intervention and does not reflect the quality of the prolonged lifetime.
The lack of efficacy in these clinical studies can have several causes. First, results that have been obtained in preclinical glioma models and that have motivated further clinical evaluation may not adequately represent the pathobiology of glioblastoma in patients. Second, the inhibitor may have failed to inactivate the target in glioblastoma cells, for instance due to low concentrations in tumor tissue or agent inactivation mechanisms. Third, the pursued kinase target may be active only in a subpopulation of patients. The efficacy of kinase inhibition in this subpopulation may have been diluted by unselected glioblastoma patients. Fourth, alternative kinase signaling pathways may be active in parallel with the inhibited target, so that a single target's inactivation does not reduce downstream oncogenic signaling. Fifth, beneficial effects from these kinase inhibitors are perhaps not portrayed by the classical endpoints as evaluated.
Several strategies may help overcome these issues. First, the best kinase drug targets need to be identified for glioblastoma. Second, the preclinical efficacy from inhibition of these drug targets needs to be rigorously verified in several glioblastoma models to complement each single model's limitations. Third, kinase inhibitors need to be developed and optimized further, for instance by directing toward downstream targets or toward multiple kinase targets or by using a combination of inhibitors. However, the toxicity of the evaluated kinase inhibitors was significant, and hence improved safety of new inhibitors remains important. Fourth, the inactivation of the target and its downstream substrate should be verified in early studies with glioblastoma tissue obtained from patients. An elegant proof-of-concept of this biological activity endpoint was recently demonstrated. 39 Fifth, the study populations need to be enriched by including patients likely to respond, by determining the activation status of the aimed drug target. Sixth, other clinical trial endpoints, such as quality of life and cognitive status, can be considered in addition to the classical trial endpoints. 47, 48 The radiological response is a useful surrogate endpoint for glioma therapy in general, because objective results are provided shortly after therapy. From the presented data, it is clear that reduction in enhancement can also be observed after kinase inhibition. The PFS6 suitably predicts OS and therefore is considered a meaningful endpoint for evaluation of progressive glioblastoma. Perhaps the ideal endpoint for assessment of clinical benefit by targeted therapy would be a multidimensional construct of imaging, symptoms, quality, progression, and survival.
A more fundamental question is whether glioblastoma is in fact a kinase-driven cancer. Undoubtedly, oncogenic kinase signaling is involved in glioblastoma, but whether kinases are crucial for the oncogenic signaling network of glioblastoma and are thereby amenable to therapeutic inhibition, remains to be determined. Kinase drug targets that have changed clinical practice in the treatment of solid cancers are dysregulated in 1 of 3 ways: by mutation, gene overexpression, or protein fusion. 49 All three relevant mechanisms of kinase dysregulation have been identified in glioblastoma, for example, mutation of PIK3CA lipid kinase, 50 overexpression of the AURKA gene, 51 and fusion of FIG to ROS kinase. 52 Details on kinase involvement in glioblastoma can be found in dedicated reviews. 9, 10, 14, 53, 54 The protein kinase gene family consists of 518 members. 55 The status of the vast majority of these kinases remains to be determined in glioblastoma, and it is unclear which kinases are best for targeting with small molecule inhibitors. Therefore, it may prove worthwhile to evaluate kinase targets other than those currently utilized for small molecule inhibition in glioblastoma. 56 Another fundamental question, if glioblastoma turns out to be kinase driven, is which strategy is best for kinase inhibition. For example, one of the more favorable responses in the clinical studies reviewed here has been observed using the FLT1/KDR inhibitor cediranib. 17 A strategy alternative for inhibition of kinase signaling other than using a small-molecule inhibitor is binding of the ligand of receptor tyrosine kinases with monoclonal antibodies. This strategy has recently been shown to hold promise as a cancer therapy for glioblastoma. 57 -59 In conclusion, this review of published clinical studies demonstrates small-molecule kinase inhibitors for adult patients with glioblastoma to be not effective enough yet to warrant a change in clinical practice, whereas the evaluated drug targets have been generally limited to EGFR, mTOR, KDR, FLT1, PKCb, and PDGFR.
